Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1980 Jun;43(6):552–554. doi: 10.1136/jnnp.43.6.552

Reversible supranuclear ophthalmoplegia associated with Parkinsonism.

R J Guiloff, R J George, C D Marsden
PMCID: PMC490600  PMID: 7205300

Abstract

Two patients presented with a supranuclear ophthalmoplegia and clinical features otherwise indistinguishable from classical Parkinson's disease. Both had intercurrent infection, and recovery from the ophthalmoplegia paralleled that from the infection, but the Parkinsonian features improved more gradually on increasing doses of levodopa.

Full text

PDF
552

Images in this article

553Image
on p.553

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Behrman S., Carroll J. D., Janota I., Matthews W. B. Progressive supranuclear palsy. Clinico-pathological study of four cases. Brain. 1969;92(3):663–678. doi: 10.1093/brain/92.3.663. [DOI] [PubMed] [Google Scholar]
  2. Corin M. S., Elizan T. S., Bender M. B. Oculomotor function in patients with Parkinson's disease. J Neurol Sci. 1972 Mar;15(3):251–265. doi: 10.1016/0022-510x(72)90068-8. [DOI] [PubMed] [Google Scholar]
  3. De Renzi E., Vignolo L. A. L-dopa for progressive supranuclear palsy. Lancet. 1969 Dec 20;2(7634):1360–1360. [PubMed] [Google Scholar]
  4. Dehaene I., Bogaerts M. L-dopa in progressive supranuclear palsy. Lancet. 1970 Aug 29;2(7670):470–470. doi: 10.1016/s0140-6736(70)90089-9. [DOI] [PubMed] [Google Scholar]
  5. Dix M. R., Harrison M. J., Lewis P. D. Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome). A report of 9 cases with particular reference to the mechanism of the oculomotor disorder. J Neurol Sci. 1971 Jul;13(3):237–256. doi: 10.1016/0022-510x(71)90029-3. [DOI] [PubMed] [Google Scholar]
  6. Gross M. L-dopa for progressive supranuclear palsy. Lancet. 1969 Dec 20;2(7634):1359–1360. [PubMed] [Google Scholar]
  7. Jenkins R. L-dopa for progressive supranuclear palsy. Lancet. 1969 Oct 4;2(7623):742–742. doi: 10.1016/s0140-6736(69)90449-8. [DOI] [PubMed] [Google Scholar]
  8. Klawans H. L., Jr L-dopa for progressive supranuclear palsy. Lancet. 1969 Dec 20;2(7634):1359–1359. [PubMed] [Google Scholar]
  9. Marsden C. D., Parkes J. D., Rees J. E. A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet. 1973 Dec 29;2(7844):1459–1462. doi: 10.1016/s0140-6736(73)92729-3. [DOI] [PubMed] [Google Scholar]
  10. STEELE J. C., RICHARDSON J. C., OLSZEWSKI J. PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol. 1964 Apr;10:333–359. doi: 10.1001/archneur.1964.00460160003001. [DOI] [PubMed] [Google Scholar]
  11. Sacks O. W. L-dopa for progressive suparanulcear palsy. Lancet. 1969 Sep 13;2(7620):591–592. doi: 10.1016/s0140-6736(69)90284-0. [DOI] [PubMed] [Google Scholar]
  12. Wagshul A., Daroff R. B. L-dopa for progressive supranuclear palsy. Lancet. 1969 Jul 12;2(7611):105–106. doi: 10.1016/s0140-6736(69)92413-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES